Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in adults with atypical hemolytic uremic syndrome
NL-OMON34263Phase 2Withdrawn
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Alexion Pharmaceuticals. Primary endpoint: Complete TMA response. Planned start Nov 2010; status: withdrawn.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NL-OMON34263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34263.